Search
Showing results for "clinical trials"
Research
Does a 10-valent pneumococcal-Haemophilus influenzae protein D conjugate vaccine prevent respiratory exacerbations in childrenOur study will be the first to assess vaccine efficacy targeting H. influenzae in children with recurrent PBB, CSLD and bronchiectasis.
News & Events
Australia’s first DNA-based COVID-19 vaccine study set to begin at The Kids Research Institute AustraliaAustralia’s first needle-free, gene-based COVID-19 vaccine study will be spear-headed in WA by The Kids Research Institute Australia thanks to almost $6 million in Coronavirus Research Response funding announced by Health Minister Greg Hunt.
Research
Kadadjiny Dwank (listening, thinking and learning with your ears), Otitis Media from an urban Aboriginal perspectiveDeborah Peter Lehmann Richmond AO, MBBS, MSc MBBS MRCP(UK) FRACP Honorary Emeritus Fellow Head, Vaccine Trials Group Honorary Emeritus Fellow Head,
Research
Prenatal omega-3 LCPUFA and symptoms of allergic disease and sensitization throughout early childhoodMaternal supplementation with 900 mg of ω-3 LCPUFA did not change the progression of IgE-mediated allergic disease symptoms or sensitization
Research
An observational study of the reactogenicity and immunogenicity of 13-valent pneumococcal conjugate vaccine in women of childbearing age in Papua New GuineaMaternal immunization with pneumococcal conjugate vaccine (PCV) may protect young infants in high-risk settings against the high risk of pneumococcal infections in early life. The aim of this study was to determine the safety and immunogenicity of 13-valent PCV (PCV13) in healthy women of childbearing age in PNG.
What would you discover to help a child? At The Kids, our researchers are committed to Autism research that makes a real difference.
Research
Topical versus systemic antibiotics for chronic suppurative otitis mediaTo assess the relative effectiveness of topical versus systemic antibiotics for people with chronic suppurative otitis media
Engaging the community in COVID-19 rapid research
Research
Effectiveness of Palivizumab against Respiratory Syncytial Virus: Cohort and Case Series AnalysisPalivizumab appeared effective for reducing virologically confirmed respiratory syncytial virus in this high-risk cohort
